PXS.LSE Provexis plc
- Market cap
- GBX 20.1M
- P/E
- -
- P/B
- 19.09x
- ROE
- -45.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is PXS.LSE undervalued?
Graham numberThe Graham number of Provexis plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Provexis plc fundamental analysis
No fundamental analysis for Provexis plc yet.
Provexis plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Provexis plc
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. It provides syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. The company also provides Fruitflow+ Omega-3, a dietary suppl…
Full company profileProvexis plc financial statements
Provexis plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 228K | 236K | 322K | 348K | 505K | 426K | 598K | 802K | 1.29M | 1.26M |
| Gross Profit | 218K | 213K | 273K | 312K | 456K | 380K | 279K | 284K | 533K | 511K |
| Operating Income | -412K | -468K | -534K | -425K | -359K | -299K | -497K | -604K | -448K | -492K |
| EBITDA | 31.9K | 19.8K | -513K | -404K | -359K | -283K | - | -604K | -450K | -492K |
| Net Income | -380K | -448K | -513K | -406K | -341K | -224K | -497K | -586K | -453K | -503K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 158K | 419K | 462K | 469K | 1.29M | 1.13M | 846K | 498K | 1.01M | 1.30M |
| Total Liabilities | 133K | 89.4K | 123K | 150K | 151K | 158K | 188K | 307K | 248K | 723K |
| Shareholders' Equity | 463K | 786K | 816K | 814K | 1.66M | 1.50M | 1.19M | 724K | 1.30M | 1.11M |
| Cash & Short-term Investments | 12.3K | 315K | 326K | 291K | 1.08M | 864K | 379K | 189K | 708K | 893K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -430K | -363K | -384K | -335K | -262K | -214K | -428K | -191K | -341K | 180K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 250.00 | 250.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -430K | -363K | -384K | -335K | -262K | -214K | -428K | -191K | -339K | 180K |
| Ratios | ||||||||||
| ROE | -82.2% | -57.0% | -62.8% | -49.9% | -20.6% | -15.0% | -41.7% | -80.9% | -34.9% | -45.5% |
| ROA | -240.3% | -107.0% | -111.0% | -86.7% | -26.4% | -19.9% | -58.7% | -117.7% | -44.7% | -38.8% |
| Net Profit Margin | -167.0% | -190.0% | -159.2% | -116.8% | -67.5% | -52.6% | -83.0% | -73.1% | -35.0% | -39.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Provexis plc dividends
Provexis plc has not paid dividends in the last 10 fiscal years.
Last stock split: 2:1 on Jun 23, 2005.
Who owns Provexis plc
- Insiders 20.85%
- Institutions 9.87%
- Public & others 69.29%
- Shares outstanding 2.35B
- Free float 1.81B
Provexis plc company profile
- Company name
- Provexis plc
- Ticker
- PXS.LSE
- ISIN
- GB00B0923P27
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- March
- Address
- 2 Blagrave Street, Reading, United Kingdom, RG1 1AZ
- Phone
- 44 7490 391888
- Website
- provexis.com
About Provexis plc
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. It provides syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. The company also provides Fruitflow+ Omega-3, a dietary supplement product. It sells its products through e-commerce website and distributors. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.
Provexis plc management
3- Mr. Ian Ford BA (Hons) ACA, F.C.A.CEO, CFO, Company Secretary & Executive Director · born 1965
- Dr. Niamh Ann O'Kennedy B.Sc., M.Sc., Ph.D.Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director · born 1973
- Prof. Asim K. Duttaroy BS MS Ph.D., DSc FICNConsultant & Member of Scientific Advisory Board